A listed biotech firm had already successfully out-licensed its lead asset. An innovative differentiated follow-on oncology asset was at the IND-enabling stage.
This additional asset had the potential to vastly amplify the company’s valuation beyond that of a single-asset.
The planned a first-in-human study for the new asset was putting it on a path leading to a commercial role that would not have been viable in the global markets.
Working with the company on a clearly-defined rationale for selection of target patient populations (and corresponding commercial roles).
Redesigning the first-in-human clinical trial strategy.
Increasing the study’s alignment with the company’s foundational scientific promise and its contribution to a cohesive capital markets narrative.
Enhancing commercial relevance to potential partners & capital markets.
Working with the company on a clearly-defined rationale for selection of target patient populations (and corresponding commercial roles).
Redesigning the first-in-human clinical trial strategy.
Redesigning the first-in-human clinical trial strategy.
Redesigning the first-in-human clinical trial strategy.
Working with the company on a clearly-defined rationale for selection of target patient populations (and corresponding commercial roles).
Redesigning the first-in-human clinical trial strategy.
Increasing the study’s alignment with the company’s foundational scientific promise and its contribution to a cohesive capital markets narrative.
Enhancing commercial relevance to potential partners & capital markets.
